Evidence map›Paper›PMID 27085355›Full record

ArticleApplied biochemistry and biotechnology2016

Selection of RNA Aptamers Against Botulinum Neurotoxin Type A Light Chain Through a Non-Radioactive Approach.

Tzuu-Wang Chang, Pavithra Janardhanan, Charlene M Mello, Bal Ram Singh, Shuowei Cai

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Applied biochemistry and biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Botulinum neurotoxin: from molecular pathogenesis to emerging countermeasures.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Tzuu-Wang ChangDepartment of Chemistry and Biochemistry, University of Massachusetts Dartmouth, 285 Old Westport Rd, North Dartmouth, MA, 02747, USA.
Pavithra JanardhananDepartment of Chemistry and Biochemistry, University of Massachusetts Dartmouth, 285 Old Westport Rd, North Dartmouth, MA, 02747, USA.
Charlene M MelloUS Army Natick Soldier Research, Development & Engineering Center, Natick, MA, 01760, USA.
Bal Ram SinghBotulinum Research Center, Institute of Advanced Sciences, Dartmouth, MA, 02747, USA.
Shuowei CaiDepartment of Chemistry and Biochemistry, University of Massachusetts Dartmouth, 285 Old Westport Rd, North Dartmouth, MA, 02747, USA. scai@umassd.edu.
University of Massachusetts Dartmouth · USCombat Capabilities Development Command Soldier Center · US

Funding

RNA aptamers as novel antidotes against botulismR21AI070787 · NIAID · UNIVERSITY OF MASSACHUSETTS DARTMOUTH · PI CAI, SHUOWEI · 2008 to 2009
$382k
NIAID NIH HHS R21 AI070787
6 · The paper itself

Abstract

Botulinum neurotoxin (BoNT), a category A agent, is the most toxic molecule known to mankind. The endopeptidase activity of light chain domain of BoNT is the cause for the inhibition of the neurotransmitter release and the flaccid paralysis that leads to lethality in botulism. Currently, antidotes are not available to reverse the flaccid paralysis caused by BoNT. In the present study, a non-radioactive-based systematic evolution of ligands by exponential enrichment (SELEX) process is developed by utilizing surface plasmon resonance to monitor the binding enrichment. Two RNA aptamers have been identified as strong binders against light chain of botulinum neurotoxin type A. These two aptamers showed strong inhibition activity on LCA, with IC50 in nanomolar range. Inhibition kinetic studies reveal mid nanomolar KI and non-competitive nature of their inhibition, suggesting that they have strong potential as antidotes that can reverse the symptom caused by BoNT/A. More importantly, we observed that the 2'-fluorine-pyrimidine-modified RNA aptamers identified here do not change their binding and biological activities. This observation could lead to a cost-effective way for SELEX, by using regular nucleotide during SELEX, and 2'-fluorine-pyrimidine-modified nucleotide for final application to enhance their RNase-resistance.

Indexed as

RadioactivityAptamers, NucleotideBase SequenceBotulinum Toxins, Type AEndopeptidasesInhibitory Concentration 50KineticsPolymerase Chain ReactionProtein BindingPyrimidinesSELEX Aptamer TechniqueSurface Plasmon ResonanceAptamers, NucleotideBotulinum Toxins, Type AEndopeptidasespyrimidinePyrimidines2′-fluorine-pyrimidineAntidoteAptamerBotulinum neurotoxinEndopeptidaseRNASurface plasmon resonance

Identifiers

PMID27085355
PMCPMC5010959
OpenAlexW2337321132

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.